European regulators have expanded the use of Bayer and Regeneron’s Eylea (aflibercept), approving the drug’s use to treat visual impairment due to macular oedema secondary to Retinal Vein Occlusion.

The indication now includes macular oedema following Branch Retinal Vein Occlusion (BRVO), adding to the previously approved macular oedema secondary to Central Retinal Vein Occlusion (CRVO).

For more details, go to: http://www.pharmatimes.com/Article/15-02-26/New_indication_for_Bayer_Regeneron_s_Eylea_in_EU.aspx